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ABSTRACT The Streptococcus pneumoniae clone Hungary19A-6 expresses unusually
high levels of -lactam resistance, which is in part due to mutations in the MurM
gene, encoding a transferase involved in the synthesis of branched peptidoglycan.
Moreover, it contains the allele ciaH232, encoding the histidine kinase CiaH (M. Mül-
ler, P. Marx, R. Hakenbeck, and R. Brückner, Microbiology 157:3104–3112, 2011, https://
doi.org/10.1099/mic.0.053157-0). High-level penicillin resistance primarily requires the
presence of low-affinity (mosaic) penicillin binding protein (PBP) genes, as, for example,
in strain Hu17, a closely related member of the Hungary19A-6 lineage. Interestingly,
strain Hu15 is -lactam sensitive due to the absence of mosaic PBPs. This unique
situation prompted us to investigate the development of cefotaxime resistance in
transformation experiments with genes known to play a role in this phenotype, pbp2x,
pbp1a, murM, and ciaH, and penicillin-sensitive recipient strains R6 and Hu15. Charac-
terization of phenotypes, peptidoglycan composition, and CiaR-mediated gene expres-
sion revealed several novel aspects of penicillin resistance. The murM gene of strain
Hu17 (murMHu17), which is highly similar to murM of Streptococcus mitis, induced
morphological changes which were partly reversed by ciaH232. murMHu17 conferred
cefotaxime resistance only in the presence of the pbp2x of strain Hu17 (pbp2xHu17). The
ciaH232 allele contributed to a remarkable increase in cefotaxime resistance in combi-
nation with pbp2xHu17 and pbp1a of strain Hu17 (pbp1aHu17), accompanied by higher
levels of expression of CiaR-regulated genes, documenting that ciaH232 responds to
PBP1aHu17-mediated changes in cell wall synthesis. Most importantly, the proportion of
branched peptides relative to the proportion of linear muropeptides increased in cells
containing mosaic PBPs, suggesting an altered enzymatic activity of these proteins.
KEYWORDS Streptococcus pneumoniae, PBP2x, PBP1a, CiaH, MurM, peptidoglycan
analysis
Streptococcus pneumoniae is a commensal bacterium that colonizes the humannasopharynx (1, 2). Moreover, it is a leading respiratory human pathogen, causing
a variety of diseases mainly in children, elderly people, and immunocompromised
patients (3, 4). S. pneumoniae has long been considered a highly -lactam-susceptible
organism. However, high-level penicillin-resistant S. pneumoniae (PRSP) strains fre-
quently express multiple antibiotic resistance genes, and their incidence has increased
dramatically since the 1980s worldwide. Only a few clones of serotypes 14, 23F, 19F,
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19A, 9V, and 6B that spread globally were mainly responsible for this scenario (5). The
introduction of a 7-valent pneumococcal conjugated vaccine in 2000 followed by a
13-valent vaccine in 2010 was associated with a decrease in the incidence of infections
due to PRSP but was accompanied by the appearance of antibiotic-resistant clones
expressing nonvaccine serotypes (6–8). This development underlines the importance of
continuing surveillance for antibiotic resistance and furthering our understanding of
resistance mechanisms.
Resistance to -lactams in S. pneumoniae is primarily driven by alterations in the
transpeptidase domain of three penicillin binding proteins (PBPs), PBP2x, PBP2b, and
PBP1a (for a review, see reference 9). These altered PBPs display a decrease in affinity
to the -lactam antibiotics, while the alterations apparently leave the enzyme function
unaffected. The DNA sequences of PBP genes in penicillin-sensitive S. pneumoniae
strains are well conserved. In contrast, the PBP genes of PRSP strains contain mosaic
sequence blocks of different lengths that may differ by over 20% at the DNA level or
10% at the amino acid level compared with the sequences of the corresponding
regions in the PBP genes of penicillin-sensitive S. pneumoniae strains (see reference 9
and references within). There is evidence that these mosaic blocks were acquired from
commensal mitis group streptococci, especially S. mitis, via homologous recombination
(10–13). Subsequent intraspecies recombination and mutations lead to the further
diversification of PBP genes, resulting in a large number of PBP alleles (14, 15).
PBP2x and PBP2b are essential proteins and represent the primary target of
-lactams (for a review, see reference 16). Mutations in each of these proteins result in
low-level -lactam resistance and can be selected in sensitive strains (17–19). In
contrast, mutations in PBP1a do not result in a detectable resistance increase if they are
not accompanied by PBP2x and/or PBP2b alterations (20). PBP2b does not interact with
third-generation cephalosporins, such as cefotaxime; therefore, it is not a target for this
class of compounds (21). Thus, PBP2b mediates resistance primarily to penicillins, such
as piperacillin, whereas high-level cefotaxime resistance requires only alterations in
PBP2x in combination with alterations in PBP1a (for reviews, see references 9 and 22).
PBPs are crucial enzymes acting in the biosynthesis of peptidoglycan (PG), a major
cell wall component that surrounds the cytoplasmic membrane and is required to
maintain the shape and osmotic stability of bacteria. Pneumococcal PG forms a
multilayered network of glycan chains of alternating N-acetylglucosamine (GlcNAc) and
N-acetylmuramic acid (MurNAc) residues connected via short stem peptides consisting
of L-Ala–-D-iGln–L-Lys–D-Ala–D-Ala (23). Unamidated glutamate is prevalent only in
monomers, indicating that the transpeptidases require fully amidated peptide sub-
strates (24). The cross-linking of stem peptides, the crucial reaction that leads to the
network structure of PG, is catalyzed by the D,D-transpeptidase activity of PBPs. In S.
pneumoniae, the stem peptides can be further modified by replacement of the L-Lys
-amino group with a dipeptide consisting of L-Ala or L-Ser followed by an invariable
L-Ala residue, resulting in branched peptides (24–26). Overall, the pneumococcal PG
consists of a complex mixture of mainly monomeric, dimeric, and trimeric peptides with
modifications in the glycan and peptide chains (24). Some PRSP clones contain in-
creased levels of branched muropeptides due to the presence of a mosaic MurM gene
(25, 27, 28) whose product, MurM, displays increased catalytic activity (29). Hence, it was
proposed that low-affinity PBPs from PRSP isolates prefer branched peptides as the
substrate (27), but experimental evidence is still lacking. Remarkably, the deletion of
murM (also called fibA) in PRSP results in a complete loss of the resistance phenotype
(30–32), a phenomenon that is not understood in molecular terms.
In addition to the PBP and MurM genes, other genes have been implicated in the
-lactam resistance of S. pneumoniae (for a review, see reference 9). The first non-PBP
gene identified in spontaneous -lactam-resistant S. pneumoniae laboratory mutants
was ciaH (33, 34), encoding the histidine kinase CiaH, part of the two-component
regulatory system CiaRH (33, 35). Mutations in CiaH result in higher levels of expression
of genes regulated by the cognate response regulator CiaR and confer a pleiotropic
phenotype: an increase in the level of -lactam resistance, prevention of competence
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development, and protection from lysis-inducing conditions (35–37). A functional
CiaRH system is required for proper growth in laboratory mutants containing altered
PBP2x (20, 37). Distinct mutations in ciaH were also identified in clinical isolates of S.
pneumoniae, including isolate Hungary19A-6 (36, 38). The ciaH alleles from laboratory
mutants of the S. pneumoniae R6 strain strongly enhance expression of the CiaR
regulon, whereas CiaH variants of clinical strains increase the activity of CiaR-dependent
promoters only moderately under the same circumstances (36).
The CiaRH system, part of a complex regulatory network, is ubiquitously present
among nonpyogenic streptococci (39, 40). The response regulator CiaR directly controls
15 promoters that drive the transcription of 29 genes; among these are 5 genes
specifying small noncoding cia-dependent small RNAs (csRNAs) (35, 41). The csRNAs
feed into another regulatory network, including the competence regulon (42). There-
fore, it is not surprising that the CiaRH system affects a variety of physiological
processes, such as -lactam resistance (33, 36), genetic competence (33, 37, 43–45),
bacteriocin production (46, 47), the maintenance of cell integrity (37, 48), and host
colonization (49). The CiaRH system was shown to be highly active and nearly consti-
tutive under a variety of laboratory conditions (50) and in animal models of colonization
and virulence (49, 51–53), but the signal detected by the sensor kinase CiaH is still
unknown.
High-level penicillin- and multiple-antibiotic-resistant serotype 19A S. pneumoniae
strains were prevalent in Hungary during the 1990s (54, 55) and occurred in the Czech
Republic and Slovakia as well (56). These type 19A isolates express a PBP3 with an
electrophoretic mobility different from that of most other S. pneumoniae isolates and
differ in their PBP2x sequences, accompanied by a variable PBP profile (57, 58), and
their genomes appear to be surprisingly variable (59). Accordingly, multilocus electro-
phoretic typing revealed several electrophoretic types (57). Multilocus sequence typing
(MLST) identified one major clone, Hungary19A-6 (representative strain HUN663, also
named Hungary19A-6), of sequence type (ST) 268 (ST268) (5). In this work, we studied
the resistance determinants in two serotype 19A strains from Hungary, strains Hu15 and
Hu17. They represent members of the same clone, ST226, a single-locus variant of
Hungary19A-6 differing in the ddl allele, encoding the D-Ala–D-Ala ligase (60). Strain
Hu15 is penicillin sensitive, whereas strain Hu17 exhibits high-level penicillin resistance;
their MIC values for benzylpenicillin are 0.06 g/ml and 24 g/ml, respectively (57). This
unique situation was used to study the development of cefotaxime resistance and to
understand the contribution of genes known to play a role in this phenotype, pbp2x,
pbp1a, murM, and ciaH, by analyzing the physiological and biochemical consequences
in mutants containing various combinations of these genes.
RESULTS
-Lactam resistance determinants in S. pneumoniae Hu17 and Hu15. To identify
penicillin resistance determinants, two strains of ST226 were chosen for genome
sequencing: Hu17, which is one of the strains with the highest levels of penicillin and
cefotaxime resistance held in the Kaiserslautern strain (KL) collection, and penicillin-
sensitive strain Hu15 (60). Genes encoding the resistance determinants PBP2x, PBP2b,
PBP1a, and MurM were analyzed in detail. All three PBP genes of Hu17 display a mosaic
structure very similar to that of the PBP genes of the Hungary19A-6 genome (GenBank
accession no. CP000936.1) (Fig. 1; see also Fig. S1 in the supplemental material). They
contain one sequence block highly divergent from the sequence of S. pneumoniae R6
that covers the transpeptidase domain (pbp2x of strain Hu17 [pbp2xHu17] and pbp1a of
strain Hu17 [pbp1aHu17]) or four smaller divergent sequence blocks in the transpepti-
dase domain (pbp2b of strain Hu17 [pbp2bHu17]) (Fig. 1 and S1). The mosaic sequence
block of pbp2xHu17 contains regions highly similar (5% divergence at the nucleotide
level) to the sequence of pbp2x of S. mitis strains M3 and NCTC10712, which is common
among the highly variable pbp2x sequences of serotype 19A isolates from Hungary (58).
In the deduced protein sequence, the two mutations T338P and Q552E, close to the
active site Ser337 and the K547SG box, respectively, are noteworthy. The combination of
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both mutations is rare and most likely contributes to the high penicillin resistance level
of Hu17. E552 is selectable with cefotaxime (19). Whereas A338 is present in mosaic
pbp2x of most PRSP isolates, P338 is uncommon and leads to higher levels of -lactam
resistance compared to those obtained with A338 (20).
The diverse block of pbp1aHu17 contains regions highly similar to the pbp1a se-
quence of S. mitis 850 (GenBank accession no. JUQO01000231) (61) interspersed with
smaller regions of unknown origin (Fig. 1 and S1). PBP1aHu17 contains the mutation
L539W and the alteration of four consecutive residues, T574SQF to NTGY, implicated in
resistance (62).
The PBP2bHu17 gene of Hu17 has four divergent sequence blocks within the
transpeptidase domain, including the mutation T446A, important for penicillin resis-
tance (17). The mosaic blocks of pbp2b are not related to any pbp2b sequence of S. mitis
in GenBank, except for a small region between codons 309 and 357 which is similar to
the pbp2b sequences of S. mitis strains DD26 (GenBank accession no. LQOD00000000.1)
(39) and SK1080 (GenBank accession no. AFQV01000033).
The murM gene of strain Hu17 (murMHu17) is identical to the murM gene of S.
pneumoniae Hungary19A-6 and displays a mosaic structure compared to S. pneumoniae
R6. Its sequence diverges from that of the murM of strain R6 (murMR6) by 17%,
resulting in 74 amino acid (aa) changes. Curiously, the murM allele is almost
identical to the murM allele of penicillin-sensitive S. mitis strain SK616 (GenBank
accession no. NZ_AICR00000000) (14), which differs by only 17 nucleotides (nt) (or 8 aa)
from the murMHu17 sequence (Fig. S2) and by 12 nt (or 5 aa) from the murM sequence
of S. pseudopneumoniae 294 (GenBank accession no. JVMO01000033) (61), which is of
unknown antibiotic susceptibility. This demonstrates that murM has also been acquired
from S. mitis, similar to mosaic blocks in the PBP genes of PRSP isolates.
In addition, Hu17 contains the unique ciaH232 allele, resulting in the mutation N78D
within the sensor domain; ciaH232 is slightly less effective than the CiaH wild type in
mediating CiaR-dependent transcription in the R6 background (36). The ciaH232 allele
does not confer -lactam resistance in the R6 background, but since other ciaH alleles
from laboratory mutants and clinical isolates mediate this phenotype (see reference 36
and references within), it was included in this study.
FIG 1 Mosaic PBPs of S. pneumoniae Hu17 and Hungary19A-6. Mosaic gene structures were deduced by
comparison of the reference PBP2x sequences of strains S. pneumoniae R6 (white) and S. mitis M3 (red),
NCTC10712 (yellow), and 850 (blue). Highly similar sequences (5% difference) are shown in the same
color; gray areas are divergent sequences of unknown origin. The numbers indicate the codons defining
the sequence blocks that diverge from the pbp2xR6 nucleotide sequence by15%. The domain structure
and active-site boxes are indicated on top; the black area represents the transpeptidase domain.
Mutations potentially relevant for the resistance phenotype are indicated.
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In penicillin-sensitive strain Hu15, the sequences of the three PBP genes are almost
identical to those in S. pneumoniae R6 and do not contain mosaic blocks (Fig. S1). The
pbp2x gene of Hu15 differs from that of R6 by 9 nt, resulting in only 1 aa change, I175V,
in the N-terminal domain, and pbp1a differs by 9 nt (PBP1a) and 3 aa changes (A124T,
A388D, and D533E), which are also present in pbp1aHu17, while pbp2b differs by 3 nt and
no amino acid changes. Surprisingly, both murMHu17 and ciaH232 are present in Hu15,
suggesting that these genes do not contribute to resistance by themselves, i.e., in the
absence of mosaic PBPs. Furthermore, this clearly documents that they were present in
this particular clone prior to the introduction of PBP genes, the major -lactam
resistance determinants.
Experimental outline. In this analysis, we focused on the development of cefo-
taxime resistance. Since PBP2b is not a target of this particular antibiotic and thus does
not contribute to cefotaxime resistance, it was not included in the experiments (21).
The genes encoding PBP2x, PBP1a, MurM, and CiaH of resistant strain Hu17 were
introduced individually or in various combinations into nonencapsulated laboratory
strain R6 (Fig. 2) to see how they affect the resistance level, as described below. In
addition, Hu15 was used as the recipient of pbp2xHu17 and pbp1aHu17 to see whether
they suffice to confer the cefotaxime resistance level of Hu17. Unlike most clinical
isolates, including the resistant members of ST226, Hu15 is readily transformable under
standard laboratory conditions and can be used in transformation experiments. Trans-
formants were named according to the transferred genes, as shown in Fig. 2.
-Lactam resistance mediated by pbp2xHu17 and pbp1aHu17. Transformations
were carried out with PCR-amplified PBPHu17 genes flanked by R6 or Hu15 sequences,
as described in the supplemental material, to ensure that only pbp2xHu17 or pbp1aHu17
and not the flanking genes were introduced into the recipient strain. Cefotaxime was
used as the selective antibiotic and was used at concentrations slightly above the MIC
values for the recipient strains (for Hu15, 0.019 g/ml; for R6, 0.018 g/ml). Between 12
and 20 transformants were analyzed after incubation with BocillinFL, followed by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and fluorog-
raphy, to identify transformants with low-affinity PBPs, and one such transformant was
used in subsequent experiments.
First, the pbp2xHu17 gene was introduced into strain Hu15. The transformant, Hu152x,
contained almost the entire transpeptidase domain of pbp2xHu17, including the de-
duced mutations P338 and E552 (Fig. 3). Subsequent transfer of pbp1aHu17 resulted in
Hu152x1a, where pbp1aHu17 was present up to codon 550, a sequence which includes
the deduced mutation W539 (Fig. 4). The MIC values of oxacillin and cefotaxime for
Hu152x were 1.5 and 0.7 g/ml, respectively (Fig. 5). The cefotaxime MIC for Hu152x1a
was 1.2 g/ml, which is significantly higher than the MIC for Hu152x and close to the
MIC for the parental strain, Hu17 (1.6 g/ml) (Fig. 5). The slight difference might be
FIG 2 Schematic representation of transformation steps. The genes of PBP2x, PBP1a, MurM, and CiaH
present in penicillin-resistant strain Hu17 (top right) were introduced individually or in various combi-
nations into sensitive nonencapsulated laboratory strain S. pneumoniae R6 or into clinical isolate Hu15,
as indicated by the colors. The direction of gene transfer is indicated by arrows. Gray circles represent
recipient strains R6 and Hu15 and donor strain Hu17. Transformants containing all four genes are
identified at the bottom and named according to the order of the transformation steps.
Interactions between PBPs, murM, and ciaH Antimicrobial Agents and Chemotherapy
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attributed to the fact that the entire pbp1aHu17 sequence, including codons 574 to 577,
is not present in Hu152x1a. In contrast, no increase in the oxacillin MIC was mediated by
pbp1aHu17; rather, a slight but reproducible decrease in the oxacillin MIC was observed
(Fig. 5). This suggests that introduction of pbp1aHu17 into this particular genetic
background requires cefotaxime selection and that the increased oxacillin resistance is
related to other genes not included in the transformation experiments. Nevertheless,
these data document that the four genes ciaH232,murMHu17, pbp2xHu17, and pbp1aHu17
suffice to mediate high levels of resistance to cefotaxime in Hu15.
The transformant R62x contained the pbp2xHu17 sequence up to codon 660, resulting
in a considerable increase in cefotaxime and oxacillin MICs (0.3 g/ml and 0.6 g/ml,
respectively) compared to those for the parental R6 strain (0.018 g/ml and 0.08 g/ml,
respectively), as expected (Fig. 3 and 5). Successive transformation of the entire
pbp1aHu17 sequence increased the resistance levels even more, especially for cefo-
taxime (0.8 g/ml); the increase in the oxacillin MIC was less pronounced (0.65 g/ml)
(Fig. 4 and 5). However, these values are below the MICs for Hu152x1a, clearly docu-
menting that at least murMHu17 contributes to -lactam resistance and ciaH232 poten-
tially contributes to -lactam resistance.
Effects of murMHu17 and ciaH232 on -lactam resistance and cell morphology
in S. pneumoniae R6. Although S. pneumoniae strains Hu15 and R6 are penicillin
susceptible, they differ slightly in their MIC values for oxacillin and cefotaxime (Fig. 6).
To assess the contribution of murMHu17 and ciaH232 to -lactam resistance, the genes
were introduced individually or in combination into S. pneumoniae R6 using the Janus
FIG 3 PBP2x variants obtained in transformation experiments. (A) PBP profiles of transformants contain-
ing mosaic PBP2x. PBPs were visualized after incubation with BocillinFL followed by separation by
SDS-PAGE and fluorography. Recipient strains S. pneumoniae R6 and Hu15 were included for comparison,
as indicated on top. The positions of the PBPs are marked on the left side. Arrowheads, low-affinity PBP2x.
(B) Schematic representation of pbp2x in transformants R62x and Hu152x compared to strains R6 (white
sequence blocks) and Hu17 (black sequence blocks). (Top row) The transpeptidase domain is shown in
black, and the active-site motifs are indicated. (C) Deduced peptide sequences of PBP2x of the
transformants compared to the peptide sequences of PBP2x of the penicillin-sensitive strain S. pneu-
moniae R6 and the donor PBP2x of Hu17. The first three lines indicate the amino acid positions. Only the
residues at positions with altered residues are shown; residues identical to those in strain R6 (bold letters)
are indicated by dots. The transpeptidase domain is shaded gray.
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counterselectable procedure (63). This avoids selection with -lactam antibiotics, and
the rpsL41 mutation, which is required for such constructs, has no effect on CiaRH-
mediated regulation or -lactam susceptibility (36).
The transformant R6 murMHu17 (R6M) grew with a longer generation time of 68 min
and a shorter stationary phase (approximately 2 h) compared to those for R6 and R6
ciaH232 (R6C) (51 min and approximately 4 h, respectively) and was only slightly but
reproducibly less susceptible to oxacillin and cefotaxime (Fig. 6A). However, the MIC
values of cefotaxime and oxacillin for R6M were still below those for Hu15. In addition,
the cell morphology of R6M was grossly altered. The cells were round, similar to Hu15
cells, and distinct from the oval-shaped cells of the parental R6 strain, and 50% of the
cells grew in chains containing occasionally enlarged or smaller cells (Fig. 6B). In
contrast, R6C grew with the same generation time as the parental R6 strain (not shown),
and its cell morphology was not affected (Fig. 6B). The visual impression was confirmed
by precise determination of the cell dimensions (see Materials and Methods). In fact, the
length and width of R6C cells (0.96 m  0.04 and 0.83 m  0.03, respectively; n 
206) were identical to the values obtained for R6 cells (0.95 m  0.04 and 0.80 m 
0.03, respectively; n  220).
Introduction of ciaH232 into R6M (R6MC) had no effect on MIC values but remarkably
affected cell morphology. R6MC cells were more oval shaped than R6M cells, and the
morphology of R6MC cells was similar to that of cells of the parental R6 strain, whereas
chain formation was more pronounced in R6MC cells than parental R6 cells (Fig. 6B). In
other words, the morphological defects caused by murMHu17 were almost reversed by
ciaH232, while cells still grew in chains, suggesting that the CiaRH system somehow
responds to the altered cell wall biochemistry mediated by murMHu17.
Effect of ciaH232 and murMHu17 on -lactam resistance in S. pneumoniae R62x
and R62x1a. In further experiments, ciaH232 andmurMHU17 were transferred into strains
FIG 4 PBP1a variants obtained in transformation experiments. (A) PBP profiles of transformants contain-
ing mosaic PBP1a. PBPs were visualized after incubation with BocillinFL followed by separation by
SDS-PAGE and fluorography. Recipient strains S. pneumoniae R6 and Hu15 were included for comparison,
as indicated on top. The positions of the PBPs are marked on the left side. Arrowheads, low-affinity PBP2x
and PBP1a. (B) Schematic representation of pbp1a in transformants compared to strains R6 (white
sequence blocks) and Hu17 (black sequence blocks). (Top row) The transpeptidase domain is shown in
black, and the active-site motifs are indicated. (C) Deduced peptide sequences of PBP1a of the
transformants compared to the peptide sequences of PBP1a of the penicillin-sensitive strain S. pneu-
moniae R6 and the donor PBP1a of Hu17. The first three lines indicate the amino acid positions. Only the
residues at positions with altered residues are shown; residues identical to those in strain R6 (bold letters)
are indicated by dots. The transpeptidase domain is shaded gray.
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R62x and an R6 strain which carried pbp2xHu17 and pbp1aHu17 (R62x1a) individually or in
combination to study their impact on resistance in the presence of pbp2xHu17 alone or
together with pbp1aHu17. The introduction of murMHu17 into R62x resulted in strain
R62xM and conferred increased cefotaxime and oxacillin MICs (Fig. 5). This demonstrates
for the first time that pbp2xHu17 alone suffices as a genetic background to reveal that
FIG 6 Cell morphology and resistance pattern of S. pneumoniae R6 transformants carrying the murM and/or ciaH
gene from strain Hu17. (A) The MIC values for the transformants are indicated as colored bars, and those for control
strains R6 and Hu15 are indicated as white bars. The two -lactams cefotaxime and oxacillin were used. Mean
values from at least three independent experiments are shown. Bars indicate standard deviations. (B) Represen-
tative phase-contrast micrographs are shown. The strains were grown in CY medium. Arrows, altered cell
morphology. Bar, 5 m.
FIG 5 Resistance patterns of various S. pneumoniae transformants. The two -lactams oxacillin and
cefotaxime were used. Mean values from at least three independent experiments are shown. Bars
indicate standard deviations. The MIC values of oxacillin and cefotaxime for the donor strain Hu17 were
30 g/ml and 1.6 g/ml, respectively.
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a mosaic murM contributes substantially to -lactam resistance. In contrast, transfer of
ciaH232 into strain R62x (R62xC) or R62xM (R62xMC) had no effect on MIC values (Fig. 5).
When transformed into R62x1a, murMHu17 resulted in a further increase in the level
of cefotaxime resistance (1.3 g/ml compared to 0.8 g/ml for R62x1a). Surprisingly,
transfer of ciaH232 into R62x1a also resulted in a significant increase in the cefotaxime
MIC value to 1.2 g/ml (Fig. 5). Resistance associated with ciaH was first observed in
laboratory mutants and led to hyperactivation of the CiaR regulon (64). Since ciaH232
does not mediate resistance by itself in the R6 background (36), this finding suggests
that ciaH232 can indeed hyperactivate the CiaR regulon but only in the presence of
both pbp1aHu17 and pbp2xHu17 (R62x1aC) and not in the sole presence of pbp2xHu17
(R62xC). This is the first time that a phenotype conferred by a ciaH allele appears to be
associated with an altered PBP1a. Moreover, this effect was seen only in the absence of
murMHu17; i.e., transfer of ciaH232 into R62x1aM did not result in a further increase in the
level of -lactam resistance (Fig. 5).
Curiously, the oxacillin resistance level of all R6 transformants containing pbp1aHu17
was clearly below the MIC for R62xM or R62xMC mediated by murMHu17, as if the
presence of pbp1aHu17 somehow suppresses themurMHu17-mediated resistance (Fig. 5).
It should also be noted that the oxacillin resistance level of Hu152x1a was almost 2-fold
higher than that of R62x1aMC. This strongly suggests the presence of unknown features
that feed into the resistance phenotype of the clone Hungary19A-6.
Activity of CiaR-controlled promoters in the presence of resistance determi-
nants. Various ciaH alleles identified in laboratory mutants contribute to resistance and
result in a hyperactive CiaRH system, whereas these features were less pronounced with
three distinct CiaH alleles of clinical isolates or even absent in the case of ciaH232 (36).
However, the effect of ciaH232 on cefotaxime resistance when it was introduced into
R62x1a as described above suggested that the CiaRH system is also hyperactive under
these conditions. Therefore, the expression of two CiaR-dependent genes encoding the
serine protease HtrA and a secreted protein of unknown function, spr0931, was tested
in different R6 derivatives using lacZ reporter assays (35, 65). The activities of both the
PhtrA and Pspr0931 promoters are strongly dependent on CiaR, and there is no evidence
that they are controlled by other regulators (35, 50). Each of the promoters was cloned
in front of a promoterless Escherichia coli lacZ gene (65) and integrated into the S.
pneumoniae R6 strain and its derivatives. We selected for further experiments strains
which carried ciaH232 in combination with altered pbp2xHu17 (R62x), strains which
carried pbp2xHu17 and pbp1aHu17 (R62x1a), strains which did not carry pbp2xHu17 (R6C),
and the parental R6 strain as a control.
-Galactosidase activities were measured in cells grown in complex C medium (66)
supplemented with 0.1% yeast extract (CY medium) at two different time points
during exponential growth (when the optical density at 600 nm [OD600] was 0.4 and
0.8) and at the onset of the stationary phase. As shown in Fig. 7A, the levels of
transcription from both promoters PhtrA and Pspr1149 were similar in all strains except
R62x1aC, where promoter activities increased more than 3-fold and were even higher at
the onset of stationary phase. These results confirmed that the CiaRH system is
hyperactive in the presence of pbp1aHu17 in combination with pbp2xHu17.
Effect of CiaH232 and mosaic PBP2xHu17/PBP1aHu17 on morphology and pep-
tidoglycan composition. The hyperactivation of CiaR observed in strain R62x1aC indi-
cates that the sensor kinase CiaH232 responds to some signal mediated by PBP1aHu17.
Since PBP1a acts as a transglycosylase/transpeptidase during PG synthesis, it is possible
that R62x1aC produces an altered PG. Therefore, transformants containing pbp2xHu17 or
both pbp2xHu17 and pbp1aHu17 with or without ciaH232 were examined microscopically,
and the PG composition of the strains was investigated.
The presence of pbp2xHu17 in R62x already resulted in cells that were enlarged and
more rounded compared to cells of the parental R6 strain, an effect which was at least
partially reverted by ciaH232 in R62xC (Fig. 7B). The additional presence of pbp1aHu17
(R62x1a) resulted in cells with more pointed ends, and chain formation and smaller cells
were frequently observed, suggesting some defects related to cell division and sepa-
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ration. Again, the subsequent introduction of ciaH232 resulted in cells that appeared
more normal in size and form (Fig. 7B). These results suggest that the function of the
products of both pbp2xHu17 and pbp1aHu17 differs from that of the respective R6
proteins and, thus, that these products affect cell morphology, whereas ciaH232
counteracts this defect.
The peptidoglycan was isolated from the transformants, and the compositions of
the muropeptides were analyzed as described previously (24). Detailed analysis of the
PG of S. pneumoniae by reversed-phase high-performance liquid chromatography
(HPLC) revealed 50 different muropeptide structures, including those carrying modifi-
cations such as deacetylation of GlcNAc residues and O-acetylation of MurNAc residues,
the presence of iGln instead of Glu, and Gly at position 5 of the stem peptide (24). In
the present study, 31 peaks which included all major muropeptides, accounting for 68
to 72% of known muropeptides, were used for the final analysis (Table S1).
All mutants retained an overall muropeptide composition similar to that of parental
strain R6 (Tables 1 and S1). Small changes (differences of up to 15% from the values for
R6) were seen in the total number of monomers, dimers, and trimers between the PG
of the strains. However, changes became evident when individual muropeptide classes
were analyzed in detail (Table 1). Remarkably, the presence of ciaH232 already resulted
in a slight increase in the amount of pentapeptides by 18% in R6C compared to R6 and
a relative increase in the ratio of indirectly cross-linked dimers versus directly cross-
linked dimers from 1.19 in R6 to 1.61 in R6C (a 35% increase compared to that in R6),
in parallel with a higher ratio of branched peptides versus linear peptides (from 0.44 to
0.51, or 16%). Moreover, the proportion of muropeptides with deacetylated GlcNAc
increased only slightly from 20.7% (R6) to 22% (Table 1). This suggests that the CiaH232
allele in not neutral for the cell and may alter the cell wall precursor metabolism to be
compatible with PBPs that prefer branched substrates.
FIG 7 -Galactosidase activities expressed from CiaR-regulated promoters and cell morphology of S.
pneumoniae R6 derivatives carrying the ciaH232 allele. (A) Strains were grown in CY medium.
-Galactosidase activities were determined at three different time points and are given in nanomoles of
nitrophenol produced per minute and milligram of protein. Mean values and standard deviations from
three independent experiments are presented. The activities of the CiaR-dependent promoters in the
R62x1aC strain were significantly different (P  0.05) from those of the promoters in the other strains. The
promoters and relevant genetic markers are indicated. (B) Phase-contrast images taken at the mid-
exponential growth phase. The strains were grown in CY medium. Arrows, altered cell morphology. Bar,
5 m.
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Major differences in muropeptide compositions were observed in constructs con-
taining the mosaic PBPs (Table 1). In all four mutants, the percentage of directly
cross-linked dimeric peptides decreased substantially, while the percentage of indirect
cross-links slightly increased, resulting in an overall slightly reduced amount of dimers.
The percentage of pentapeptides, muropeptides with deacetylated GlcNAc, and
branched peptides increased further in all strains containing mosaic PBP genes. The
additional presence of ciaH232 (R62xC) had no effect compared to the effect on R62x. In
R62x1a, indirectly cross-linked dimers were present almost twice as often as directly
cross-linked peptides, and the proportion of muropeptides with deacetylated GlcNAc
increased slightly to 25%. In other words, the presence of PBP2xHu17 and PBP1aHu17 as
well resulted in a different PG composition, indicating that their alterations apparently
affected their substrate specificity, and surprisingly, ciaH232 also had an impact on the
muropeptide profile.
Nevertheless, our PG analysis shows the remarkable robustness of PG synthesis in S.
pneumoniae that allows the cell to produce an almost normal PG with an altered
regulatory CiaRH system and two mosaic synthases, PBP2x and PBP1a, which lead in
their original strain background to a different, more branched PG. Yet this specificity of
the PBPs does cause structural changes in the PG, including a decrease in direct
cross-links and an increase in pentapeptides and deacetylated muropeptides, which
may contribute to the morphological defects observed.
DISCUSSION
The results presented here reveal new aspects of resistance development in clinical
isolates of S. pneumoniae by analyzing the physiological consequences associated
with the transfer of resistance determinants into laboratory strain R6. The high-level
penicillin-resistant clone Hungary19A-6 contains four genes involved in cefotaxime
resistance: the well-known penicillin target enzymes PBP2x and PBP1a and the non-PBP
genes murM and ciaH232. We used the unique situation of penicillin-sensitive strain
Hu15, which is of the same sequence type (ST226) as strain Hu17 and which contains
both an altered murM and the ciaH232 allele, to show that these two genes were
already present before the introduction of altered PBP genes, i.e., most likely long
before the extensive use of -lactam antibiotics triggered the evolution of PRSP. In the
following sections we discuss features associated with these four genes.
pbp2x and pbp1a. Both pbp2xHu17 and pbp1aHu17 represent rare mosaic variants
similar to alleles present in other Hungary isolates of ST226 (57, 58) (Fig. 1; see also Fig.
TABLE 1 Cell wall muropeptide compositions of S. pneumoniae R6 and mutant strains
Muropeptide
Relative peak area (%) or ratio in straina:
R6 R6C R62x R62xC R62x1a R62x1aC
Monomers 56.8 0.8 56.9 1.2 60.1 0.1 61.0 1.7 60.5 0.2 59.4 1.1
Dimers 39.0 0.8 38.6 1.6 35.2 0.1 34.4 1.6 34.9 0.1 35.7 1.2
Trimers 4.2 0.0 4.5 0.3 4.7 0.3 4.7 0.1 4.6 0.2 4.9 0.1
Tripeptides 65.7 0.8 65.1 0.3 64.4 1.2 64.6 0.8 64.3 0.6 64.4 1.5
Tetrapeptides 26.1 0.9 26.5 1.2 25.2 0.6 25.1 0.2 26.3 1 26.1 0.5
Pentapeptides 6.0 1.4 7.1 1.4 9.4  1.7 9.3  0.6 8.7  1.6 8.8  1.0
Peptides in cross-links 43.2 0.8 43.1 1.2 39.9 0.2 39.0 1.7 39.5 0.2 40.6 1.1
Directly cross-linked dimers 17.8 1.0 14.8 0.8 13.2 0.6 13.2 0.9 11.8  0.5 12.5 1.0
Indirectly cross-linked dimers 21.2 1.8 23.8 0.8 22.0 0.5 21.2 0.7 23.2 0.6 23.2 0.2
Ratio of indirectly cross-linked dimers/
directly cross-linked dimers
1.19 1.61 1.7 1.61 1.97 1.86
Linear peptides 63.9 2.4 60.7 1.3 59.5 2.1 59.5 1.0 57.4 0.8 57.5 0.6
Branched peptidesb 27.9 1.9 30.9 1.1 32.2 2.1 31.7 0.7 32.6 0.2 33.2 0.5
Ratio of branched peptides/linear
peptides
0.44 0.51 0.54 0.53 0.57 0.58
Deacetylation 20.7 0.1 21.9 0.1 23.0 1.9 23.3 0.7 25.0 3.2 24.0 0.2
aThe values are means  variations for two independent PG preparations. Laura software (Lab Logic Systems Ltd) was used for peak area quantification. The relative
peak areas were estimated as the percentage of all known peaks. Underlined values were considered to be significantly different by more than 15% from the value
for strain R6; bold underlined values were significantly different by more than 30% from the value for R6.
bMuropeptides with an SA or AA branch.
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S1 in the supplemental material). Both PBPs contain mutations close to active-site
motifs. P338 and E552 in PBP2xHu17 have been shown experimentally to play a role in
resistance development (19, 20). Also, the change Q599P, a mutation at a site which is
affected in high-level cefotaxime-resistant strain S. mitis B6 (W599) (67), might contrib-
ute to the high level of cefotaxime resistance of strain Hu17. There are other alterations
in PBP2xHu17 frequently found in PBP2x of PRSP strains: A369V, I371T, N444S, and S531K
(15). The alterations A279G, I318L, E320K, T401I, Q405E, A410T, V544I, L565T, and S612V have
not yet been described, and it remains to be clarified experimentally whether these
changes contribute to resistance. All other alterations occur in the parental sequence
blocks related to S. mitis strains M3 and NCTC10712.
PBP1aHu17 clearly contributes to cefotaxime resistance but only slightly contributes
to oxacillin resistance (58), indicating that its mutations primarily affect the interaction
with cefotaxime. Similar results were obtained when mosaic PBP genes of the clone
Spain23F-1 were transferred into the R6 strain (20). Curiously, the oxacillin resistance
level of all R6 transformants containing pbp1aHu17 was clearly below the MIC of R62xM
or R62xMC mediated bymurMHu17, as if the presence of pbp1aHu17 somehow suppresses
themurMHu17-mediated resistance (Fig. 5). The oxacillin resistance level of Hu152x1a was
almost 2-fold higher than that of R62x1aMC, strongly suggesting the presence of
unknown features that feed into the resistance phenotype of the ST226 strains.
The A124T and E388D mutations in PBP1a lead to strong suppression of the essen-
tiality of mreCD. PBP1a and MreCD are components proposed to be part of the same
protein complex involved in peripheral PG synthesis (68). These changes are not
present in strain R6 but are present in strains Hu15 and Hu17. It should also be noted
that mraY, located downstream of pbp2x, is highly altered in strains Hu17 and Hu15.
MraY is an essential phospho-N-acetylmuramoyl pentapeptide transferase in PG syn-
thesis. These gene products could have an impact on cell morphology and PG com-
position in the Hungary19A-6 clone and might affect PBP function indirectly.
Although the overall PG composition appeared to be similar in all constructs
analyzed, differences which affected the ratio of individual muropeptides, the substrate,
and the product of PBPs were revealed. These differences could be due to modifications
in the availability of the different substrates or to endopeptidases hydrolyzing the PG
cross-links. However, we believe it to be more likely that the PBPs themselves were
responsible for these changes. All R6 derivatives containing PBP2xHu17 or both
PBP2xHu17 and PBP1aHu17 showed an increased ratio of indirectly over directly cross-
linked dimers, ranging from an increase compared to the ratio in R6 of 43% in R62x to
65% in R62x1a (Table 1). This implies that both PBPs have an altered substrate specificity
and prefer branched over linear peptides as the substrate, as has been previously
suggested (27). We have now demonstrated for the first time experimentally an impact
of individual mosaic PBPs on PG composition. Enzymatic analyses of purified PBPs are
required to reveal in detail the differences in the kinetic properties of PBPs between
resistant strains and sensitive strains.
The R6 strain used in the present study has mostly linear peptides but a higher
percentage of branched peptides and indirect cross-links than its progenitor strains,
D39 and R36A (24, 26, 28, 69). Therefore, it is possible that mosaic PBPs can affect the
PG composition more prominently in different genetic backgrounds.
There were other differences in muropeptide composition that cannot be explained
by the sole action of PBP2x and PBP1a. The increase in pentapeptides in strains with the
mosaic pbp2x gene suggests either that the trimming of nascent pentapeptides to
tetra- and tripeptides by PBP3 (70) and LdcB (DacB) (71) is affected or that the overall
synthesis of PG is increased to an extent that pentapeptides are not trimmed fast
enough. Notably, the cells of R62x and R62x1a exhibited morphological defects similar to
those of cells of a dacB deletion strain (72). Finally, strains with mosaic PBP genes
contained more deacetylated muropeptides; whether this was due to an increased
activity of the PG deacetylase PgdA remains to be clarified (73).
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Effects mediated by murMHu17. The presence of an altered MurM gene in PRSP
isolates of serotype 19A strains from Hungary and its contribution to penicillin resis-
tance in the presence of altered PBP genes have previously been described for strains
Hun663 (30, 74) and 3191 (32). In contrast, many other PRSP clones do not contain
mosaic MurM genes, including the clone Taiwan19F-14 and serotype 19A switch variants
thereof (75) and the clonal complex Spain23F-1. The mosaic murM was present not only
in penicillin-resistant strain Hu17, as expected, but also, as shown here for the first time,
in penicillin-sensitive strain Hu15, which does not contain mosaic PBP genes. The gene
murMHu17 is highly related to murM of the penicillin-sensitive S. mitis strain SK616 (14),
differing in only 5 aa, strongly suggesting that it was acquired from S. mitis. This is not
surprising, given the fact that Hungary19A-6 had acquired the largest proportion of
genes (8.2%) from S. mitis in a comparative genomic analysis of 35 Streptococcus species
genomes (76).
Two amino acid changes in MurMHu17 are present in the region between residues
244 and 274 proposed to be important for the contribution to penicillin resistance (77):
K266 and P267. When introduced into S. pneumoniae R6, murMHu17 contributed only
marginally to -lactam resistance (Fig. 5); similarly, only a small increase in -lactam
susceptibility has been noted in R6 derivatives with a deleted murM (31). Previous
analyses have studied the effect of murM only in the presence of multiple mosaic PBP
genes (30, 32). As shown here, MurMHu17 already caused changes in morphology and
growth in the R6 background (Fig. 6), and a substantial increase in -lactam resistance
was observed when it was introduced into R62x; i.e., MurMHu17 does not require PBP1a
to mediate a clear resistance effect (Fig. 5). Thus, it could well be that the presence of
the mosaic murM is not related to a selective advantage during exposure to -lactams
but that it has been circulating in this clone long before the transfer of PBP sequences.
In agreement with this, the MurM gene in strains Hu15, Hu17, and Hungary19A-6,
including the upstream gene encoding a putative tributyrin esterase, is completely
conserved, whereas PBP genes and flanking regions (pbp2x and mraY, clpL; recU and
pbp1a; pbp2b and ddl) are diverse, as has been described in other PRSP isolates (78).
This scenario suggests that the mosaic PBPs, after all essential enzymes, must cope with
MurMHu17 with different enzymatic properties (29), resulting in the abundant presence
of branched muropeptides (27), i.e., the substrates of PBPs. In other words, some
mutations in the mosaic PBPs might be related to an altered substrate pool and not
necessarily to -lactam resistance in this particular genetic background.
The allele ciaH232. Almost no effects of ciaH232 on -lactam resistance or the
expression of CiaR-regulated genes were observed when it was introduced into the R6
strain, in contrast to the findings for ciaH alleles from laboratory mutants (36). However,
cells containing ciaH232 reacted more strongly to the presence of acetate in the
medium (79). In the present study, some new features of ciaH232 that are associated
with cell morphology, -lactam resistance, and cell wall composition were revealed.
The first example refers to the comparison of the transformants R6M and R6MC, where
R6M cells grew with an aberrant morphology, whereas R6MC cells were indistinguish-
able from those of the parental R6 strain (Fig. 5). Similarly, the morphological changes
induced by PBP2xHu17 and PBP1aHu17 were compensated for by the presence of
ciaH232 (Fig. 7B). This suggests that CiaH232 apparently responds to alterations medi-
ated directly or indirectly by the resistance determinants of Hu17 to ensure proper cell
growth. Second, cefotaxime resistance was further increased when ciaH232 was trans-
formed into R62x1a but not into R62x (Fig. 6), and the CiaR-regulated genes htrA and
spr0931 showed higher expression levels only in R62x1aC (Fig. 7A). The N78D mutation
of CiaH232 is located in the sensor domain of the histidine protein kinase, in agreement
with an altered signal recognition site outside the cell membrane, mediated by
murMHu17 and pbp1aHu17 or pbp2xHu17. Thus, it is possible that the CiaH mutation
expressed by ciaH232 is a response to the presence of murMHu17 in the Hungary19A-6
strain.
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These data were complemented by cell wall analysis, which revealed changes in the
PG composition in R6 derivatives containing pbp1aHu17 and/or pbp2xHu17 (Tables 1 and
S1); murM-mediated changes in PG composition have been reported before (30, 74).
Curiously, enhanced expression of the CiaR-regulated genes was observed only in
R62x1aC and not in R62xC, similar to previous reports that showed that the wild-type ciaH
allele did not affect htrA expression in the presence of PBP2x point mutations or
another mosaic PBP2x from a clinical isolate (37). However, CiaR activation by CiaH from
clinical isolates of S. pneumoniae was far less pronounced than that by CiaH from
laboratory mutants (36). This is an indication that mutations in PBP2x and CiaH selected
with -lactams in laboratory mutants affect the function of both proteins differently
and with a more detrimental outcome to the cells compared to the outcome resulting
from mutated alleles in clinical isolates. Altogether this scenario adds another facet to
the interplay between the CiaRH system and PBPs and differences in PBP mutations of
laboratory mutants versus clinical isolates.
Most intriguing was the finding that the muropeptide composition was affected by
ciaH232 (R6C) in the absence of PBPsHu17: an increase in the amount of pentapeptides
by 18%, an increased proportion of indirectly cross-linked dimers (12%), and more
muropeptides containing a deacetylated GlcNAc (5.8%). The values are less than those
seen for R62x and R62x1a but concern the same muropeptide classes. These data are in
agreement with the assumption that the CiaRH system somehow controls the overall
composition of the pneumococcal cell wall to ensure its integrity (20, 37).
Concluding remarks. In the early 1990s, the penicillin resistance of pneumococci
was considered to be entirely due to altered PBPs (80). The non-PBP components CiaH
and MurM have since been recognized to be relevant players in resistance develop-
ment in laboratory mutants and clinical isolates, respectively. The present analysis
revealed that the CiaH232 allele of the S. pneumoniae clone Hungary19A-6 responds to
the presence of MurMHu17. The contribution to -lactam resistance of these two genes
in combination with mosaic PBP genes carrying mutations known to be relevant for
resistance development became evident. The interplay between the cytoplasmic MurM
involved in the biosynthesis of PG precursors, transpeptidases controlling the PG
cross-linkage at the outer surface of the cell wall (PBP2x and PBP1a), and the sensor
histidine protein kinase CiaH mediating signals from the outside to the response
regulator CiaR is schematically shown in Fig. 8. Taken together, the data reveal a highly
complex network that ensures the synthesis of a functional bacterial cell wall under
antibiotic stress.
FIG 8 Schematic view of the interactions between MurM, PBPs, and the CiaRH system. Black, a branched
muropeptide; red, L-Ala in the interpeptide bridge added by MurMHu17; gray: cell wall; black line, cell
membrane. See the text for details.
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MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains used in this study are
listed in Table 2. S. pneumoniae strains were grown at 37°C without aeration in complex C medium (66)
supplemented with 0.1% yeast extract (CY medium) or in brain heart infusion (BHI; Roth) medium, and
growth was followed by monitoring the optical density at 600 nm (OD600). Strains were grown on D-agar
plates (81) supplemented with 3% defibrinated sheep blood.
Promoter-probe plasmid pPP2 containing the htrA and spr0931 promoters and plasmid pPP2 have
been described previously (35, 65). For cloning and propagation of plasmids, Escherichia coli strain DH5
was used as a host. E. coli strains were grown aerobically at 37°C either in LB medium or on LB agar plates
(82). The growth of E. coli was followed by measuring the OD600 using a spectrophotometer.
Microscopy and growth curves. For physiological and morphological analysis, cells were inoculated
in prewarmed CY or BHI medium and grown at 37°C without aeration. Cell growth was monitored by
spectroscopy at OD600. At an OD600 of 0.7, cultures were diluted 1:20 in the respective prewarmed
medium, and growth was followed throughout the growth cycle. For microscopic analysis, 5 l of
exponential growing cells at an OD600 of 0.7 was transferred to poly-L-lysine-coated slides and analyzed
by phase-contrast microscopy using an Eclipse E600 (Nikon) microscope equipped with a 100 oil
immersion objective (numerical aperture, 1.4). Photographs were taken with a DXM1200C camera
(Nikon). Image analysis and determination of the cell size were carried out using Nikon Nis-Elements BR
(version 3.2) imaging software. For physiological and morphological analyses, the cells from three
separate cultures were analyzed, and at least two photographs of each culture were taken.
Transformation procedure. Transformation of the S. pneumoniae strains was carried out as de-
scribed previously (37). When required, the growth media for S. pneumoniae were supplemented with
the following antibiotics: 200 g/ml kanamycin (Kan), 200 g/ml streptomycin (Str), 3 g/ml tetracycline
(Tet), or 20 g/ml spectinomycin (Spc). The -lactam concentrations used to select mosaic pbp2x and
pbp1a are specified in the supplemental material.
E. coli DH5 was transformed by using chemically competent cells (82), and transformants were
selected in the presence of 100 g/ml ampicillin or 50 g/ml spectinomycin.
Antibiotic susceptibility. The MICs of the -lactam antibiotics were determined by the agar dilution
method on D-agar plates supplemented with 3% sheep blood under a natural atmosphere. Cells were
grown in CY medium to an OD600 of 0.3, and after 1,000-fold dilution, 30-l aliquots were spotted onto
D-agar plates containing the appropriate antibiotic. In order to detect minor differences in -lactam
susceptibilities, a narrow range of antibiotic concentrations was used. In detail, for strains R6, R6C, R6M,
R6MC, and Hu15, concentration steps of 0.01 g/ml for oxacillin and 0.012 g/ml for cefotaxime were
used, and for the remaining strains, concentration steps of 0.1 g/ml for oxacillin and cefotaxime
were used. The MICs for S. pneumoniae Hu17 were determined with Etest strips (Oxoid GmbH). The
MIC values were obtained after incubation at 37°C for 48 h. Mean values from at least three
experiments were used.
Determination of -galactosidase activity. Determination of -galactosidase activity in strains
carrying CiaR-controlled promoters in front of a promoterless E. coli lacZ gene was performed as
TABLE 2 S. pneumoniae strains used in this study
Strain Relevant characteristics
Reference(s)
or source
R6a Unencapsulated laboratory strain, -lactam susceptible 85, 86
Hu15 Serotype 19A isolate from Hungary, -lactam susceptible 57
Hu17 Serotype 19A isolate from Hungary, -lactam resistant 57
CCCOmurM::Janus CCCO murM::Kanr rpsL rpsL41 Kanr Strr 12
CCCOmurMHu17 CCCO murMHu17 rpsL41 Strr 12
RKL243 R6 ciaH232 rpsL41 Strr 36
RKL248 RKL243 bgaA::tet(M)-PhtrA Strr Tetr 36
RKL249 RKL243 bgaA::tet(M)-Pspr0931 Strr Tetr 36
RKL161 R6 ciaH::Kanr rpsL rpsL41 Kanr Strs 36
R6strR R6 rpsL41 Strr This study
R6M R6 murMHu17 rpsL41 Strr This study
R6MC R6M ciaH232 Strr This study
R62xa R6 pbp2xHu17 This study
R62xCa R62x ciaH232 rpsL41 Strr This study
R62xM R62x murMHu17 rpsL41 Strr This study
R62xMC R62xM ciaH232 Strr This study
R62x1aa R62x pbp1aHu17 This study
R62x1aM R62x1a murMHu17 rpsL41 Strr This study
R62x1aCa R62x1a ciaH232 Strr This study
R62x1aMC R62x1aM ciaH232 Strr This study
Hu152x Hu15 pbp2xHu17 This study
Hu152x1a Hu152x pbp1aHu17 This study
aThe promoter-probe plasmids carrying htrA or spr0931 promoter fragments (35) were integrated into the
bgaA locus of R6 derivatives; therefore, the strains are deficient in endogenous -galactosidase activity due
to disruption of bgaA.
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described previously (65). The cultures were grown in CY or BHI medium, and -galactosidase activity
was measured at three time points: when the OD600 was 0.4 and 0.8 and at the beginning of the
stationary phase. The volume of the culture harvested for one measurement was adjusted to contain the
equivalent of 2 ml cells at an OD600 of 0.8. Specific -galactosidase activities are expressed in
nanomoles of nitrophenol released per minute and milligram of protein. Protein concentrations
were determined by the method of Bradford (83). Student’s t test was applied to determine the
significance of the results.
Detection of penicillin binding proteins. Preparation of samples, PBP labeling with BocillinFL, and
separation of proteins by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) were
carried out as described previously (84). BocillinFL-PBP complexes were visualized by fluorography
detection with a FluorImager 595 fluorescence scanner (Molecular Dynamics) at 488 nm.
Preparation of pneumococcal cell wall. Pneumococcal cell wall preparation and analysis of
muropeptides were carried out as described previously (24). Briefly, pneumococci were cultured in 2 liters
of CY medium to the mid-exponential growth phase (OD600, 0.6 to 0.7) and then harvested and
resuspended in 40 ml of ice-cold 50 mM Tris-HCl, pH 7.0. The cell suspension was added dropwise into
a flask with 150 ml of boiling 5% SDS, and the sample was boiled for an additional 30 min. The samples
were centrifuged at 130,000  g at 25°C, and the pellet was washed with deionized water until it was
free of SDS. The lysed cells were disrupted with glass beads, and the sample was treated with DNase I
(10 g/ml) and RNase I (50 g/ml) for 2 h at 37°C with stirring in 100 mM Tris-HCl, pH 7.5, containing
20 mM MgSO4. Trypsin (100 g/ml) and CaCl2 (10 mM) were added, and the sample was incubated
overnight at 37°C with stirring. SDS was added to yield a final concentration of 1%, and the samples were
boiled for 15 min. The resulting purified cell wall was recovered by ultracentrifugation, washed so that
it was free of SDS (see above), and lyophilized.
Preparation of muropeptides and analysis of peptidoglycan composition. Experiments for
preparation of muropeptides and analysis of the peptidoglycan composition were performed as de-
scribed previously (24). In brief, secondary cell wall polymers were removed by incubation with 48%
hydrofluoric acid for 48 h at 4°C. The resulting PG was recovered by centrifugation, washed, and digested
with the muramidase Cellosyl for 48 h at 37°C with stirring. The samples were boiled for 10 min at 100°C,
and the muropeptides were reduced with sodium borohydride. Reduced muropeptides were separated
by HPLC on a 250- by 4.6-mm 3-m-particle-size Prontosil 120-3-6 C18 AQ reversed-phase column
(Bischoff, Leonberg, Germany). The eluted muropeptides were detected by their absorbance at 205 nm
and assigned by their retention times.
DNA manipulations and construction of mutants. All DNA techniques and the construction of
strains are described in the supplemental material.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00414-17.
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